Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated RT, Bevacizumab, and Temozolomide in Recurrent High-Grade Gliomas
NCT01478321Phase 2Terminated
- Sponsor
- Northwestern University
- Start
- Dec 2011
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in glioblastoma (GBM), anaplastic glioma, anaplastic astrocytoma (AA), anaplastic ependymoma, anaplastic oligodendroglioma (AO), sponsored by Northwestern University. Started Dec 2011; status: terminated.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)anaplastic gliomaanaplastic astrocytoma (AA)anaplastic ependymomaanaplastic oligodendroglioma (AO)
Beyond the preview
Go deeper on NCT01478321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01478321.